Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
Zanubrutinib is indicated for the treatment of:
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Peking University People's Hospital, Beijing, Beijing, China
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, China
The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.